Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.

Peter Jirak; Dzeneta Fejzic; Vera Paar; Bernhard Wernly; Rudin Pistulli; Ilonka Rohm; Christian Jung; Uta Hoppe; P Christian Schulze; Michael Lichtenauer; Atilla Yilmaz; Daniel Kretzschmar

doi:10.1038/aps.2017.167

Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.

Peter Jirak (Erstautor/-in)
, Dzeneta Fejzic (Co-Autor/-in)
, Vera Paar (Co-Autor/-in)
, Bernhard Wernly (Co-Autor/-in)
, Rudin Pistulli
, Ilonka Rohm
, Christian Jung
, Uta Hoppe (Co-Autor/-in)
, P Christian Schulze
, Michael Lichtenauer (Co-Autor/-in)
, Atilla Yilmaz
, Daniel Kretzschmar

Universitätsklinik für Innere Medizin 2 - Kardiologie, Internistische Intensivmedizin und Notaufnahme

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

25 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	1189-1196
Fachzeitschrift	ACTA PHARMACOLOGICA SINICA
Jahrgang	39
Ausgabenummer	7
DOIs	https://doi.org/10.1038/aps.2017.167
Publikationsstatus	Veröffentlicht - 2018

Zugriff auf Dokument

10.1038/aps.2017.167

Dieses zitieren

Jirak, P., Fejzic, D., Paar, V., Wernly, B., Pistulli, R., Rohm, I., Jung, C., Hoppe, U., Schulze, P. C., Lichtenauer, M., Yilmaz, A., & Kretzschmar, D. (2018). Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure. ACTA PHARMACOLOGICA SINICA, 39(7), 1189-1196. https://doi.org/10.1038/aps.2017.167

@article{c76b1086cbff43858bd76d8e6c6f9c53,

title = "Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.",

keywords = "CORONARY-ARTERY-DISEASE, ACID-BINDING PROTEIN, EJECTION FRACTION, CONTROLLED-TRIAL, SOLUBLE ST2, RISK-FACTOR, DYSFUNCTION, MANAGEMENT, DIAGNOSIS, INFLAMMATION",

author = "Peter Jirak and Dzeneta Fejzic and Vera Paar and Bernhard Wernly and Rudin Pistulli and Ilonka Rohm and Christian Jung and Uta Hoppe and Schulze, \{P Christian\} and Michael Lichtenauer and Atilla Yilmaz and Daniel Kretzschmar",

note = "Jirak, Fejzic, Paar, Wernly, Hoppe, Lichtenauer, : Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria",

year = "2018",

doi = "10.1038/aps.2017.167",

language = "English",

volume = "39",

pages = "1189--1196",

journal = "ACTA PHARMACOLOGICA SINICA",

issn = "1671-4083",

number = "7",

}

Jirak, P, Fejzic, D, Paar, V , Wernly, B, Pistulli, R, Rohm, I, Jung, C, Hoppe, U, Schulze, PC, Lichtenauer, M, Yilmaz, A & Kretzschmar, D 2018, 'Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.', ACTA PHARMACOLOGICA SINICA, Jg. 39, Nr. 7, S. 1189-1196. https://doi.org/10.1038/aps.2017.167

Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure. / Jirak, Peter (Erstautor/-in); Fejzic, Dzeneta (Co-Autor/-in); Paar, Vera (Co-Autor/-in) et al.
in: ACTA PHARMACOLOGICA SINICA, Jahrgang 39, Nr. 7, 2018, S. 1189-1196.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure.

AU - Jirak, Peter

AU - Fejzic, Dzeneta

AU - Paar, Vera

AU - Wernly, Bernhard

AU - Pistulli, Rudin

AU - Rohm, Ilonka

AU - Jung, Christian

AU - Hoppe, Uta

AU - Schulze, P Christian

AU - Lichtenauer, Michael

AU - Yilmaz, Atilla

AU - Kretzschmar, Daniel

N1 - Jirak, Fejzic, Paar, Wernly, Hoppe, Lichtenauer, : Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria

PY - 2018

Y1 - 2018

KW - CORONARY-ARTERY-DISEASE

KW - ACID-BINDING PROTEIN

KW - EJECTION FRACTION

KW - CONTROLLED-TRIAL

KW - SOLUBLE ST2

KW - RISK-FACTOR

KW - DYSFUNCTION

KW - MANAGEMENT

KW - DIAGNOSIS

KW - INFLAMMATION

U2 - 10.1038/aps.2017.167

DO - 10.1038/aps.2017.167

M3 - Original Article

C2 - 29239349

SN - 1671-4083

VL - 39

SP - 1189

EP - 1196

JO - ACTA PHARMACOLOGICA SINICA

JF - ACTA PHARMACOLOGICA SINICA

IS - 7

ER -